Metronomic chemotherapy: new rationale for new directions
Top Cited Papers
- 8 June 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 7 (8), 455-465
- https://doi.org/10.1038/nrclinonc.2010.82
Abstract
Tumor angiogenesis is recognized as a major therapeutic target in the fight against cancer. The key involvement of angiogenesis in tumor growth and metastasis has started to redefine chemotherapy and new protocols have emerged. Metronomic chemotherapy, which is intended to prevent tumor angiogenesis, is based on more frequent and low-dose drug administrations compared with conventional chemotherapy. The potential of metronomic chemotherapy was revealed in animal models a decade ago and the efficacy of this approach has been confirmed in the clinic. In the past 5 years, multiple clinical trials have investigated the safety and efficacy of metronomic chemotherapy in a variety of human cancers. While the results have been variable, clinical studies have shown that these new treatment protocols represent an interesting alternative for either primary systemic therapy or maintenance therapy. We review the latest clinical trials of metronomic chemotherapy in adult and pediatric cancer patients. Accumulating evidence suggests that the efficacy of such treatment may not only rely on anti-angiogenic activity. Potential new mechanisms of action, such as restoration of anticancer immune response and induction of tumor dormancy are discussed. Finally, we highlight the research efforts that need to be made to facilitate the optimal development of metronomic chemotherapy.Keywords
This publication has 120 references indexed in Scilit:
- A phase 2 pilot trial of low‐dose, continuous infusion, or “metronomic” paclitaxel and oral celecoxib in patients with metastatic melanomaCancer, 2010
- Biomarkers of response and resistance to antiangiogenic therapyNature Reviews Clinical Oncology, 2009
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant MetastasisCancer Cell, 2009
- Systems Biology: A Therapeutic Target for Tumor TherapyCancer Microenvironment, 2008
- Immunological aspects of cancer chemotherapyNature Reviews Immunology, 2008
- Molecular and cellular biomarkers for angiogenesis in clinical oncologyDrug Discovery Today, 2007
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 2006
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- Metronomic scheduling: the future of chemotherapy?The Lancet Oncology, 2001